Serina Therapeutics, Inc. (SER)
Recent Filing Index
| Form | Filed | Qtr End | F_Period | 8K: Earnings Release |
|---|---|---|---|---|
| 10-QLatest | Q1-2026 | 8-K (2026-05-14) · 99.1 | ||
| 10-K/A | FY-2025 | |||
| 10-KLatest | FY-2025 | 8-K (2026-03-25) · 99.1 | ||
| 10-Q | Q3-2025 | 8-K (2025-11-13) · 99.1 | ||
| 10-Q | Q2-2025 | 8-K (2025-08-11) · 99.1 | ||
| 10-Q | Q1-2025 | 8-K (2025-05-08) · 99.1 | ||
| 10-K | FY-2024 | 8-K (2025-03-24) · 99.1 | 8-K (2025-01-06) · 99.1 | ||
| 10-Q | Q3-2024 | 8-K (2024-11-12) · 99.1 | ||
| 10-Q | Q2-2024 | 8-K (2024-08-09) · 99.1 | ||
| 10-Q | Q1-2024 | 8-K (2024-05-14) · 99.1 | ||
| 10-K | FY-2023 | 8-K (2024-03-22) · 99.1 | ||
| 10-Q | Q3-2023 | 8-K (2023-11-14) · 99.1 | ||
| 10-Q | Q2-2023 | 8-K (2023-08-14) · 99.1 |
Filing Summary
| Report Name | Notes | Fiscal Period (Annual) | Fiscal Period (Quarter) |
|---|---|---|
| Cover | ||
| Audit Information | — |
|
| Statements | ||
| Consolidated Balance Sheets | ||
| Consolidated Balance Sheets (P) | ||
| Consolidated Statements of Operations | ||
| Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders' (deficit) | — |
|
| Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders' Deficit | — |
|
| Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity | — |
|
| Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Deficit | — |
|
| Consolidated Statements of Comprehensive Loss | ||
| Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity/(deficit) | — |
|
| Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (P) | — |
|
| Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Deficit (P) | — |
|
| Condensed Consolidated Statements of Stockholders Equity (deficit) (P) | — |
|
| Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity/(deficit) | — |
|
| Consolidated Statements of Stockholders' Deficit (unaudited) | — |
|
| Consolidated Statements of Cash Flows | ||
| Consolidated Statements of Convertible Preferred Stock and Stockholders' (deficit) Equity | — |
|
| Condensed Consolidated Statements of Stockholders Equity (deficit) | — |
|
| Consolidated Statements of Convertible Preferred Stock and Stockholders' (deficit) Equity (P) | — |
|
| Notes | ||
| Basis of Presentation and Summary of Significant Accounting Policies | ||
| Commitments and Contingencies | ||
| Convertible Note Receivable | ||
| Cybersecurity Risk Management and Strategy Disclosure | — |
|
| Fair Value Measurements | ||
| Grant Revenues | — |
|
| Income Taxes | ||
| Insider Trading Arrangements | ||
| Insider Trading Policies and Procedures | — |
|
| License Revenue | — |
|
| Net (loss) Income Per Common Share | — |
|
| Net Earnings (loss) Per Common Share | ||
| Net Loss Per Common Share | ||
| Organization, Basis of Presentation and Liquidity | — |
|
| Organization, Business Overview and Liquidity | ||
| Pay Vs Performance Disclosure | ||
| Profit Sharing Plan | ||
| Recapitalization | ||
| Related Party Transactions | ||
| Segment Reporting | ||
| Selected Balance Sheet Components | ||
| Stock-based Awards | ||
| Stockholders (deficit) Equity | — |
|
| Stockholders Deficit | — |
|
| Stockholders Equity | — |
|
| Stockholders Equity (deficit) | — |
|
| Stockholders Equity/(deficit) | ||
| Subsequent Events | ||
| Summary of Significant Accounting Policies | — |
|
| Supplemental Cash Flow Information | — |
|
| Warrant Liability | ||